ERBB2 and breast cancer: Recently, for the first time, we showed that daily oral 10 mg/kg OC prevented the locoregional recurrence of the ER+/HER2+ BC in a nude mouse orthotopic xenograft model after primary tumor surgical excision and after neoadjuvant lapatinib regimen completion and in adjuvant treatment mode [47].